BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30268859)

  • 1. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
    Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
    Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
    Robin P; Le Roux PY; Planquette B; Accassat S; Roy PM; Couturaud F; Ghazzar N; Prevot-Bitot N; Couturier O; Delluc A; Sanchez O; Tardy B; Le Gal G; Salaun PY;
    Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism.
    Robin P; Le Roux PY; Le Moigne E; Planquette B; Prévot-Bitot N; Roy PM; Pastre J; Merah A; Couturaud F; Le Gal G; Salaun PY
    Thromb Res; 2017 Jul; 155():6-9. PubMed ID: 28460260
    [No Abstract]   [Full Text] [Related]  

  • 4. Performance of
    Robin P; van Es N; Le Roux PY; Rondina M; Lecumberri R; Beckers M; Le Gal G; Salaun PY
    Thromb Res; 2020 Oct; 194():153-157. PubMed ID: 32788108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism.
    Rondina MT; Wanner N; Pendleton RC; Kraiss LW; Vinik R; Zimmerman GA; Heilbrun M; Hoffman JM; Morton KA
    Thromb Res; 2012 Jan; 129(1):22-7. PubMed ID: 21802118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for occult malignancy with FDG-PET/CT in patients with unprovoked venous thromboembolism.
    Alfonso A; Redondo M; Rubio T; Del Olmo B; Rodríguez-Wilhelmi P; García-Velloso MJ; Richter JA; Páramo JA; Lecumberri R
    Int J Cancer; 2013 Nov; 133(9):2157-64. PubMed ID: 23616232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of 18F-fluorodesoxyglucose positron-emission tomography combined with low-dose computed tomography for cancer screening in patients with unprovoked venous thromboembolism.
    Robin P; Le Roux PY; Lacut K; Planquette B; Prévot-Bitot N; Lavigne C; Pastre J; Merah A; Le Gal G; Salaun PY
    PLoS One; 2017; 12(6):e0178849. PubMed ID: 28570648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism.
    Coyle K; Carrier M; Lazo-Langner A; Shivakumar S; Zarychanski R; Tagalakis V; Solymoss S; Routhier N; Douketis J; Coyle D
    Thromb Res; 2017 Mar; 151():67-71. PubMed ID: 28160670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for Occult Cancer in Unprovoked Venous Thromboembolism.
    Carrier M; Lazo-Langner A; Shivakumar S; Tagalakis V; Zarychanski R; Solymoss S; Routhier N; Douketis J; Danovitch K; Lee AY; Le Gal G; Wells PS; Corsi DJ; Ramsay T; Coyle D; Chagnon I; Kassam Z; Tao H; Rodger MA;
    N Engl J Med; 2015 Aug; 373(8):697-704. PubMed ID: 26095467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism.
    Robin P; Otten HM; Delluc A; van Es N; Carrier M; Salaün PY; Le Gal G
    Thromb Res; 2018 Nov; 171():92-96. PubMed ID: 30268858
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Delluc A; Robin P
    Thromb Res; 2022 May; 213 Suppl 1():S42-S45. PubMed ID: 36210560
    [No Abstract]   [Full Text] [Related]  

  • 12. Positron emission tomography combined with computed tomography as a screening tool for occult malignancy in patients with unprovoked venous thromboembolism: an observational study.
    Chauchard M; Benali K; Papo T; Sacre K
    Medicine (Baltimore); 2014 Nov; 93(21):e110. PubMed ID: 25380083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism and occult cancer: impact on clinical practice.
    Gheshmy A; Carrier M
    Thromb Res; 2016 Apr; 140 Suppl 1():S8-11. PubMed ID: 27067984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occult cancer and thromboembolism: current epidemiology and its practical implications.
    Chao CH; Wang HY; Kao CH
    Pol Arch Intern Med; 2018 Sep; 128(9):539-544. PubMed ID: 30057385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the use of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the workup of Staphylococcus aureus bacteraemia: a cost-utility analysis.
    Ong SWX; Zhabokritsky A; Daneman N; Tong SYC; Wijeysundera HC
    Clin Microbiol Infect; 2023 Nov; 29(11):1417-1423. PubMed ID: 37353076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism.
    Ihaddadene R; Corsi DJ; Lazo-Langner A; Shivakumar S; Zarychanski R; Tagalakis V; Solymoss S; Routhier N; Douketis J; Le Gal G; Carrier M
    Blood; 2016 Apr; 127(16):2035-7. PubMed ID: 26817957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of
    Caspersen KB; Giannoutsou N; Gerke O; Alavi A; Høilund-Carlsen PF; Hess S
    Ann Nucl Med; 2019 Mar; 33(3):184-192. PubMed ID: 30569441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism.
    Robin P; Le Roux PY; Tromeur C; Planquette B; Prévot-Bitot N; Lavigne C; Pastre J; Merah A; Couturaud F; Le Gal G; Salaun PY
    Thromb Res; 2017 Nov; 159():48-51. PubMed ID: 28978463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.